

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068813 A2

(51) International Patent Classification⁷: **C07K 14/315**

(21) International Application Number: PCT/CA03/00186

(22) International Filing Date: 11 February 2003 (11.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/354,947 11 February 2002 (11.02.2002) US

(71) Applicant (*for all designated States except US*): **SHIRE BIOCHEM INC** [CA/CA]; 275 Armand-Frappier Boulevard, Laval, Quebec H7V 4A7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RIOUX, Stéphane** [CA/CA]; 869 Avenue Des Pinsons, Beauport, Québec G1E 1J3 (CA). **MARTIN, Denis** [CA/CA]; 4728-G Gaboury, St-Augustin-de-Desmaures, Québec G3A 1E9 (CA). **HAMEL, Josée** [CA/CA]; 2401 Maritain, Sillery, Quebec G1T 1N6 (CA). **BRODEUR, Bernard, R.** [CA/CA]; 2401 Maritain, Sillery, Québec G1T 1N6 (CA).

(74) Agents: **MORROW, Joy, D.** et al.; Smart & Biggar, P.O. Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GROUP B STREPTOCOCCUS ANTIGENS

1 GMTPEAATTI VSPMKTYSSA PALKSKEVLA QEQAVSQAAA NEQVSTAPVK SITSEVPAAK
61 EEVKPTQTSV SQSTTVSPAS VAAETPAPVA KVAPVRTVAA PRVASVKVVT PKVETGASPE
121 HVSAPAVPVT TTSTATDSKL QATEVKSVPV AQKAPTATPV AQPASTTNAV AAHPENAGLQ
181 PHVAAYKEKV ASTYGVNEFS TYRAGDPGDH GKGLAVDFIV GKNQALGNEV AQYSTQNMAA
241 NNISYVIWQQ KFYSNTNSIY GPANTWNAMP DRGGVTANHY DHVHVSFNNK

(57) Abstract: The present invention relates to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B streptococcus (GBS), also called Streptococcus Agalactiae which may be used to prevent, diagnose and/or treat streptococcal infection.



WO 03/068813 A2

GROUP B STREPTOCOCCUS ANTIGENSFIELD OF THE INVENTION

5

The present invention is related to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B streptococcus (GBS), also called Streptococcus Agalactiae which may be used to prevent, diagnose
10 and/or treat streptococcal infection.

BACKGROUND OF THE INVENTION

15 Streptococcus are gram (+) bacteria that are differentiated by group specific carbohydrate antigens A through O found on their cell surface. Streptococcus groups are further distinguished by type-specific capsular polysaccharide antigens. Several serotypes have been identified for the Group B streptococcus
20 (GBS): Ia, Ib, II, III, IV, V, VI, VII and VIII. GBS also contains antigenic proteins known as "C-proteins" (alpha, beta, gamma and delta), some of which have been cloned.

Although GBS is a common component of the normal human vaginal
25 and colonic flora this pathogen has long been recognized as a major cause of neonatal sepsis and meningitis, late-onset meningitis in infants, postpartum endometritis as well as mastitis in dairy herds. Expectant mothers exposed to GBS are at risk of postpartum infection and may transfer the infection to
30 their baby as the child passes through the birth canal. Although the organism is sensitive to antibiotics, the high attack rate and rapid onset of sepsis in neonates and meningitis in infants results in high morbidity and mortality.

35 GBS infections in infants are restricted to very early infancy. Approximately 80% of infant infections occur in the first days of life, so-called early-onset disease. Late-onset infections occur in infants between 1 week and 2 to 3 months of age. Clinical syndromes of GBS disease in newborns include sepsis,

meningitis, pneumonia, cellulitis, osteomyelitis, septic arthritis, endocarditis, epiglottitis. In addition to acute illness due to GBS, which is itself costly, GBS infections in newborns can result in death, disability, and, in rare
5 instances, recurrence of infection. Although the organism is sensitive to antibiotics, the high attack rate and rapid onset of sepsis in neonates and meningitis in infants results in high morbidity and mortality.

10 Among pregnant women, GBS causes clinical illness ranging from mild urinary tract infection to life-threatening sepsis and meningitis, including also osteomyelitis, endocarditis, amniotitis, endometritis, wound infections (postcesarean and postepisiotomy), cellulitis, fasciitis.

15

Among non-pregnant adults, the clinical presentations of invasive GBS disease most often take the form of primary bacteremia but also skin or soft tissue infection, pneumonia, urosepsis, endocarditis, peritonitis, meningitis, empyema. Skin
20 of soft tissue infections include cellulitis, infected peripheral ulcers, osteomyelitis, septic arthritis and decubiti or wound infections. Among people at risk, there are debilitated hosts such as people with a chronic disease such as diabetes mellitus and cancer, or elderly people.

25

GBS infections can also occur in animals and cause mastitis in dairy herds.

To find a vaccine that will protect individuals from GBS
30 infection, researchers have turned to the type-specific antigens. Unfortunately these polysaccharides have proven to be poorly immunogenic in humans and are restricted to the particular serotype from which the polysaccharide originates. Further, capsular polysaccharide antigens are unsuitable as a
35 vaccine component for protection against GBS infection.

Others have focused on the C-protein beta antigen which demonstrated immunogenic properties in mice and rabbit models. This protein was found to be unsuitable as a human vaccine
40 because of its undesirable property of interacting with high

affinity and in a non-immunogenic manner with the Fc region of human IgA. The C-protein alpha antigens is rare in type III serotypes of GBS which is the serotype responsible for most GBS mediated conditions and is therefore of little use as a vaccine component.

PCT WO 99/42588 has been published February 17, 1999 entitled 'Group B streptococcus antigens' describing the polypeptide ID-42 which is claimed to be antigenic. This polypeptide is now known under the name Sip, for Surface immunogenic protein (Brodeur et al., 2000, Infect. Immun. 68:5610).

This polypeptide was found to be highly conserved and produced by every GBS examined to date, which included representative isolates of all serotypes (Brodeur et al., 2000, Infect. Immun. 68:5610). This 53-kDa polypeptide is recognized by the human immune system. More importantly, immunization of adult mice with the Sip-polypeptide was shown to induce a strong specific antibody response and to confer protection against experimental infection with GBS strains representing serotypes Ia/c, Ib, II/R, III, V and VI (Brodeur et al.). It was also demonstrated that Sip-specific antibodies recognized their epitopes at the cell surfaces of different GBS strains, which included representatives of all nine serotypes (Rioux et al., 2001, Infect. Immun. 69:5162). In addition, it was recently reported that passive administration of rabbit anti-Sip serum to pregnant mice or immunization of female mice before pregnancy with purified recombinant Sip conferred protective immunity to their offsprings against GBS infection (Martin et al. Abstr. 101th Gen. Meet. Am. Soc. Microbiol. 2001).

Therefore there remains an unmet need for Group B Streptococcus polypeptides that may be used to prevent, diagnose and/or treat Group B Streptococcus infection. Data describing the localization of surface-accessible regions on the Sip polypeptide of Group B Streptococcus are presented. Examples presenting the utilization of these surface-accessible regions for vaccine development are also presented.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID Nos : 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

In other aspects, there are provided polypeptides encoded by polynucleotides of the invention, pharmaceutical compositions, vectors comprising polynucleotides of the invention operably linked to an expression control region, as well as host cells transfected with said vectors and processes for producing polypeptides comprising culturing said host cells under conditions suitable for expression.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 represents the DNA sequence of Asip-1 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 1).

Figure 2 represents the amino acid sequence of Δ Sip-1 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 2).

Figure 3 represents the DNA sequence of Asip-2 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 3).

Figure 4 represents the amino acid sequence of Δ Sip-2 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 4).

Figure 5 represents the DNA sequence of Asip-3 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 5).

Figure 6 represents the amino acid sequence of Δ Sip-3 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 6).

5 Figure 7 represents the DNA sequence of Δ sip-4 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 7).

Figure 8 represents the amino acid sequence of Δ Sip-4 polypeptide
10 from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 8).

Figure 9 represents the DNA sequence of Δ sip-5 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 15 9).

Figure 10 represents the amino acid sequence of Δ Sip-5 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 10).

20

Figure 11 represents the DNA sequence of Δ sip-6 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 11).

25 Figure 12 represents the amino acid sequence of Δ Sip-6 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 12).

Figure 13 represents the DNA sequence of Δ sip-7 gene from
30 serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 13).

Figure 14 represents the amino acid sequence of Δ Sip-7 polypeptide from serotype I a/c Group B streptococcus strain
35 C388/90; (SEQ ID NO: 14).

Figure 15 represents the DNA sequence of Δsip-8 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 15).

5 Figure 16 represents the amino acid sequence of ΔSip-8 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 16).

Figure 17 represents the DNA sequence of Δsip-9 gene from
10 serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 17).

Figure 18 represents the amino acid sequence of ΔSip-9 polypeptide from serotype I a/c Group B streptococcus strain
15 C388/90; (SEQ ID NO: 18).

Figure 19 represents the DNA sequence of Δsip-10 gene from serotype Ia/c Group B streptococcus strain C388/90; (SEQ ID NO: 19).

20

Figure 20 represents the amino acid sequence of ΔSip-10 polypeptide from serotype I a/c Group B streptococcus strain C388/90; (SEQ ID NO: 20).

25

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides purified and isolated polynucleotides, which encode Streptococcus polypeptides which
30 may be used to prevent, diagnose and/or treat Streptococcus infection.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least
35 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or 5 fragments or analogs thereof.

According to one aspect, the present invention provides an isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence 10 chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

According to one aspect, the present invention provides a polynucleotide encoding an epitope bearing portion of a 15 polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 or fragments or analogs or thereof.

According to one aspect, the present invention relates to 20 epitope bearing portions of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 or fragments or analogs or thereof.

According to one aspect, the present invention provides an 25 isolated polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20.

According to one aspect, the present invention provides an 30 isolated polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20.

According to one aspect, the present invention provides an 35 isolated polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20.

According to one aspect, the present invention provides a 40 polynucleotide encoding an epitope bearing portion of a

polypeptide comprising a sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20.

According to one aspect, the present invention relates to epitope bearing portions of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20.

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- 10 (a) a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from : SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
- (b) a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID
15 NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
- (c) a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or
20 analogs thereof;
- (d) a polypeptide capable of generating antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
- 25 (e) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
- (f) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
- 30 (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the secretory amino acid sequence is deleted.

According to one aspect, the present invention provides an isolated polypeptide comprising a polypeptide chosen from:

- 35 (a) a polypeptide having at least 70% identity to a second polypeptide comprising an amino acid sequence chosen from: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
- (b) a polypeptide having at least 95% identity to a second polypeptide comprising an amino acid sequence chosen
40 from: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;

- (c) a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
- (d) a polypeptide capable of generating antibodies having binding specificity for a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
- (e) an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
- (f) the polypeptide of (a), (b), (c), (d) or (e) wherein the N-terminal Met residue is deleted;
- (g) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the secretory amino acid sequence is deleted.

According to one aspect, the present invention relates to polypeptides which comprise an amino acid sequence chosen from SEQ ID Nos : 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

According to one aspect, the present invention relates to polypeptides which comprise an amino acid sequence chosen from SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20.

Those skilled in the art will appreciate that the invention includes DNA molecules, i.e. polynucleotides and their complementary sequences that encode analogs such as mutants, variants, homologues and derivatives of such polypeptides, as described herein in the present patent application. The invention also includes RNA molecules corresponding to the DNA molecules of the invention. In addition to the DNA and RNA molecules, the invention includes the corresponding polypeptides and monospecific antibodies that specifically bind to such polypeptides.

In a further embodiment, the polypeptides in accordance with the present invention are antigenic.

In a further embodiment, the polypeptides in accordance with the present invention are immunogenic.

In a further embodiment, the polypeptides in accordance with the present invention can elicit an immune response in a host.

In a further embodiment, the present invention also relates to 5 polypeptides which are able to raise antibodies having binding specificity to the polypeptides of the present invention as defined above.

An antibody that "has binding specificity" is an antibody that 10 recognizes and binds the selected polypeptide but which does not substantially recognize and bind other molecules in a sample, e.g., a biological sample. Specific binding can be measured using an ELISA assay in which the selected polypeptide is used as an antigen.

15

In accordance with the present invention, "protection" in the biological studies is defined by a significant increase in the survival curve, rate or period. Statistical analysis using the Log rank test to compare survival curves, and Fisher exact test 20 to compare survival rates and numbers of days to death, respectively, might be useful to calculate P values and determine whether the difference between the two groups is statistically significant. P values of 0.05 are regarded as not significant.

25

In an additional aspect of the invention there are provided antigenic/immunogenic fragments of the polypeptides of the invention, or of analogs thereof.

30 The fragments of the present invention should include one or more such epitopic regions or be sufficiently similar to such regions to retain their antigenic/immunogenic properties. Thus, for fragments according to the present invention the degree of identity is perhaps irrelevant, since they may be 100% identical 35 to a particular part of a polypeptide or analog thereof as described herein. The present invention further provides fragments having at least 10 contiguous amino acid residues from the polypeptide sequences of the present invention. In one embodiment, at least 15 contiguous amino acid residues. In one 40 embodiment, at least 20 contiguous amino acid residues.

The terms "fragment" or "variant," when referring to a polypeptide of the invention, mean a polypeptide which retains substantially at least one of the biological functions or activities of the polypeptide. Such a biological function or activity can be, *e.g.*, any of those described above, and includes having the ability to react with an antibody, *i.e.*, having an epitope-bearing peptide. Fragments or variants of the polypeptides, *e.g.* of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20, have sufficient similarity to those polypeptides so that at least one activity of the native polypeptides is retained. Fragments or variants of smaller polypeptides, *e.g.*, of the polypeptides of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20, retain at least one activity (*e.g.*, an activity expressed by a functional domain thereof, or the ability to react with an antibody or antigen-binding fragment of the invention) of a comparable sequence found in the native polypeptide.

The key issue, once again, is that the fragment retains the antigenic/immunogenic properties.

The skilled person will appreciate that analogs of the polypeptides of the invention will also find use in the context of the present invention, *i.e.* as antigenic/immunogenic material. Thus, for instance proteins or polypeptides which include one or more additions, deletions, substitutions or the like are encompassed by the present invention.

As used herein, "fragments", "analogs", "variants" or "derivatives" of the polypeptides of the invention include those polypeptides in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably conserved) and which may be natural or unnatural. In one embodiment, derivatives and analogs of polypeptides of the invention will have about 70% identity with those sequences illustrated in the figures or fragments thereof. That is, 70% of the residues are the same. In a further embodiment, polypeptides will have greater than 80% identity. In a further embodiment, polypeptides will have greater than 85% identity. In a further embodiment, polypeptides will have greater than 90%

identity. In a further embodiment, polypeptides will have greater than 95% identity. In a further embodiment, polypeptides will have greater than 99% identity. In a further embodiment, analogs of polypeptides of the invention will have 5 fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

A variant of a polypeptide of the invention may be, *e.g.*, (i) one in which one or more of the amino acid residues are substituted 10 with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the polypeptide is fused 15 with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which additional amino acids are fused to the polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the polypeptide, commonly 20 for the purpose of creating a genetically engineered form of the protein that is susceptible to secretion from a cell, such as a transformed cell. The additional amino acids may be from a heterologous source, or may be endogenous to the natural gene.

25 These substitutions are those having a minimal influence on the secondary structure and hydropathic nature of the polypeptide. Preferred substitutions are those known in the art as conserved, *i.e.* the substituted residues share physical or chemical properties such as hydrophobicity, size, charge or functional 30 groups. These include substitutions such as those described by Dayhoff, M. in *Atlas of Protein Sequence and Structure* 5, 1978 and by Argos, P. in *EMBO J.* 8, 779-785, 1989. For example, amino acids, either natural or unnatural, belonging to one of the following groups represent conservative changes:

35 ala, pro, gly, gln, asn, ser, thr, val;
cys, ser, tyr, thr;
val, ile, leu, met, ala, phe;
lys, arg, orn, his;
and phe, tyr, trp, his.

The preferred substitutions also include substitutions of D-enantiomers for the corresponding L-amino acids.

Variant polypeptides belonging to type (i) above include, *e.g.*,
5 muteins, analogs and derivatives. A variant polypeptide can differ
in amino acid sequence by, *e.g.*, one or more additions,
substitutions, deletions, insertions, inversions, fusions, and
truncations or a combination of any of these. Variant
polypeptides belonging to type (ii) above include, *e.g.*, modified
10 polypeptides. Known polypeptide modifications include, but are
not limited to, glycosylation, acetylation, acylation, ADP-
ribosylation, amidation, covalent attachment of flavin, covalent
attachment of a heme moiety, covalent attachment of a nucleotide
or nucleotide derivative, covalent attachment of a lipid or lipid
15 derivative, covalent attachment of phosphatidylinositol, cross-
linking, cyclization, disulfide bond formation, demethylation,
formation of covalent crosslinks, formation of cystine, formation
of pyroglutamate, formylation, gamma carboxylation, glycosylation,
GPI anchor formatin, hydroxylation, iodination, methylation,
20 myristoylation, oxidation, proteolytic processing,
phosphorylation, prenylation, racemization, selenoylation,
sulfation, transfer-RNA mediated addition of amino acids to
proteins such as arginylation, and ubiquitination.

25 Such modifications are well-known to those of skill in the art and
have been described in great detail in the scientific literature.
Several particularly common modifications, glycosylation, lipid
attachment, sulfation, gamma-carboxylation of glutamic acid
residues, hydroxylation and ADP-ribosylation, for instance, are
30 described in many basic texts, such as *Proteins--Structure and
Molecular Properties*, 2nd ed., T.E. Creighton, W.H. Freeman and
Company, New York (1993). Many detailed reviews are available on
this subject, such as by Wold, F., *Posttranslational Covalent
Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New
35 York 1-12 (1983); Seifter et al. (1990) *Meth. Enzymol.* 182:626-646
and Rattan et al. (1992) *Ann. N.Y. Acad. Sci.* 663:48-62.

Variant polypeptides belonging to type (iii) are well-known in the
art and include, *e.g.*, PEGulation or other chemical modifications.

Variants polypeptides belonging to type (iv) above include, e.g., preproteins or proproteins which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide. Variants include a variety of hybrid, chimeric or fusion
5 polypeptides. Typical example of such variants are discussed elsewhere herein.

Many other types of variants are known to those of skill in the art. For example, as is well known, polypeptides are not always
10 entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of post-translation events, including natural processing events and events brought about by human manipulation which do not occur naturally.
15 Circular, branched and branched circular polypeptides may be synthesized by non-translational natural processes and by synthetic methods.

Modifications or variations can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the
20 amino or carboxyl termini. The same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain more than one type of modification. Blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in
25 naturally-occurring and synthetic polypeptides. For instance, the aminoterminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, is often N-formylmethionine. The modifications can be a function of how the protein is made. For recombinant polypeptides, for example, the modifications are
30 determined by the host cell posttranslational modification capacity and the modification signals in the polypeptide amino acid sequence. Accordingly, when glycosylation is desired, a polypeptide can be expressed in a glycosylating host, generally a eukaryotic cell. Insect cells often carry out the same
35 posttranslational glycosylations as mammalian cells and, for this reason, insect cell expression systems have been developed to efficiently express mammalian proteins having native patterns of glycosylation. Similar considerations apply to other modifications.

Variant polypeptides can be fully functional or can lack function in one or more activities, *e.g.*, in any of the functions or activities described above. Among the many types of useful variations are, *e.g.*, those which exhibit alteration of catalytic activity. For example, one embodiment involves a variation at the binding site that results in binding but not hydrolysis, or slower hydrolysis, of cAMP. A further useful variation at the same site can result in altered affinity for cAMP. Useful variations also include changes that provide for affinity for another cyclic nucleotide. Another useful variation includes one that prevents activation by protein kinase A. Another useful variation provides a fusion protein in which one or more domains or subregions are operationally fused to one or more domains or subregions from another phosphodiesterase isoform or family.

15

In an alternative approach, the analogs could be fusion polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the desired polypeptide. It may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

The percentage of homology is defined as the sum of the percentage of identity plus the percentage of similarity or conservation of amino acid type.

In one embodiment, analogs of polypeptides of the invention will have about 70% homology with those sequences illustrated in the figures or fragments thereof. In a further embodiment, polypeptides will have greater than 80% homology. In a further embodiment, polypeptides will have greater than 85% homology. In a further embodiment, polypeptides will have greater than 90% homology. In a further embodiment, polypeptides will have greater than 95% homology. In a further embodiment, polypeptides will have greater than 99% homology. In a further embodiment, analogs of polypeptides of the invention will have fewer than about 20 amino acid residue substitutions, modifications or deletions and more preferably less than 10.

One can use a program such as the CLUSTAL program to compare amino acid sequences. This program compares amino acid sequences and finds the optimal alignment by inserting spaces in either sequence as appropriate. It is possible to calculate
5 amino acid identity or homology for an optimal alignment. A program like BLASTx will align the longest stretch of similar sequences and assign a value to the fit. It is thus possible to obtain a comparison where several regions of similarity are found, each having a different score. Both types of identity
10 analysis are contemplated in the present invention.

In an alternative approach, the analogs or derivatives could be fusion polypeptides, incorporating moieties which render purification easier, for example by effectively tagging the
15 desired protein or polypeptide, it may be necessary to remove the "tag" or it may be the case that the fusion polypeptide itself retains sufficient antigenicity to be useful.

In an additional aspect of the invention there are provided
20 antigenic/immunogenic fragments of the proteins or polypeptides of the invention, or of analogs or derivatives thereof.

Thus, what is important for analogs, derivatives and fragments is that they possess at least a degree of the
25 antigenicity/immunogenic of the protein or polypeptide from which they are derived.

Also included are polypeptides which have fused thereto other compounds which alter the polypeptides biological or
30 pharmacological properties i.e. polyethylene glycol (PEG) to increase half-life; leader or secretory amino acid sequences for ease of purification; prepro- and pro- sequences; and (poly)saccharides.

35 Furthermore, in those situations where amino acid regions are found to be polymorphic, it may be desirable to vary one or more particular amino acids to more effectively mimic the different epitopes of the different Streptococcus strains.

Moreover, the polypeptides of the present invention can be modified by terminal $-NH_2$ acylation (eg. by acetylation, or thioglycolic acid amidation, terminal carboxy amidation, e.g. with ammonia or methylamine) to provide stability, increased
5 hydrophobicity for linking or binding to a support or other molecule.

Also contemplated are hetero and homo polypeptide multimers of the polypeptide fragments and analogs. These polymeric forms
10 include, for example, one or more polypeptides that have been cross-linked with cross-linkers such as avidin/biotin, glutaraldehyde or dimethylsuberimide. Such polymeric forms also include polypeptides containing two or more tandem or inverted contiguous sequences, produced from multicistronic
15 mRNAs generated by recombinant DNA technology. In a further embodiment, the present invention also relates to chimeric polypeptides which comprise one or more polypeptides or fragments or analogs thereof as defined in the figures of the present application.

20

In a further embodiment, the present invention also relates to chimeric polypeptides comprising two or more polypeptides having a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof; provided that the
25 polypeptides are linked as to form a chimeric polypeptide.

In a further embodiment, the present invention also relates to chimeric polypeptides comprising two or more polypeptides having a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16,
30 18 or 20 provided that the polypeptides are linked as to form a chimeric polypeptide.

Preferably, a fragment, analog or derivative of a polypeptide of the invention will comprise at least one antigenic region i.e.
35 at least one epitope.

In order to achieve the formation of antigenic polymers (i.e. synthetic multimers), polypeptides may be utilized having bishaloacetyl groups, nitroarylhalides, or the like, where the
40 reagents being specific for thio groups. Therefore, the link

between two mercapto groups of the different polypeptides may be a single bond or may be composed of a linking group of at least two, typically at least four, and not more than 16, but usually not more than about 14 carbon atoms.

5

In a particular embodiment, polypeptide fragments and analogs of the invention do not contain a methionine (Met) starting residue. Preferably, polypeptides will not incorporate a leader or secretory sequence (signal sequence). The signal portion of
10 a polypeptide of the invention may be determined according to established molecular biological techniques. In general, the polypeptide of interest may be isolated from a Streptococcus culture and subsequently sequenced to determine the initial residue of the mature protein and therefore the sequence of the
15 mature polypeptide.

In another embodiment, the polypeptides of the invention may be lacking an N-terminal leader peptide, and/or a transmembrane domain and/or a C-terminal anchor domain.

20

The present invention further provides a fragment of the polypeptide comprising substantially all of the extra cellular domain of a polypeptide which has at least 70% identity, preferably 80% identity, more preferably 95% identity, to a
25 second polypeptide comprising a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20 or fragments or analogs thereof, over the entire length of said sequence.

It is understood that polypeptides can be produced and/or used
30 without their start codon (methionine or valine) and/or without their leader peptide to favor production and purification of recombinant polypeptides. It is known that cloning genes without sequences encoding leader peptides will restrict the polypeptides to the cytoplasm of E. coli and will facilitate
35 their recovery (Glick, B.R. and Pasternak, J.J. (1998) Manipulation of gene expression in prokaryotes. In "Molecular biotechnology: Principles and applications of recombinant DNA", 2nd edition, ASM Press, Washington DC, p.109-143).

According to another aspect of the invention, there are also provided (i) a composition of matter containing a polypeptide of the invention, together with a carrier, diluent or adjuvant; (ii) a pharmaceutical composition comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iii) a vaccine comprising a polypeptide of the invention and a carrier, diluent or adjuvant; (iv) a method for inducing an immune response against Streptococcus, in a host, by administering to the host, an immunogenically effective amount of a polypeptide of the invention to elicit an immune response, e.g., a protective immune response to Streptococcus; and particularly, (v) a method for preventing and/or treating a Streptococcus infection, by administering a prophylactic or therapeutic amount of a polypeptide of the invention to a host in need.

15

Before immunization, the polypeptides of the invention can also be coupled or conjugated to carrier proteins such as tetanus toxin, diphtheria toxin, hepatitis B virus surface antigen, poliomyelitis virus VP1 antigen or any other viral or bacterial toxin or antigen or any suitable proteins to stimulate the development of a stronger immune response. This coupling or conjugation can be done chemically or genetically. A more detailed description of peptide-carrier conjugation is available in Van Regenmortel, M.H.V., Briand J.P., Muller S., Plaué S., «Synthetic Polypeptides as antigens» in Laboratory Techniques in Biochemistry and Molecular Biology, Vol.19 (ed.) Burdou, R.H. & Van Knippenberg P.H. (1988), Elsevier New York.

According to another aspect, there are provided pharmaceutical compositions comprising one or more Streptococcus polypeptides of the invention in a mixture with a pharmaceutically acceptable adjuvant. Suitable adjuvants include (1) oil-in-water emulsion formulations such as MF59™, SAF™, Ribi™ ; (2) Freund's complete or incomplete adjuvant; (3) salts i.e. $AlK(SO_4)_2$, $AlNa(SO_4)_2$, $AlNH_4(SO_4)_2$, $Al(OH)_3$, $AlPO_4$, silica, kaolin; (4) saponin derivatives such as Stimulon™ or particles generated therefrom such as ISCOMs (immunostimulating complexes); (5) cytokines such as interleukins, interferons, macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF) ; (6) other substances such as carbon polynucleotides i.e. poly IC and poly

AU, detoxified cholera toxin (CTB) and E.coli heat labile toxin for induction of mucosal immunity; (7) liposomes. A more detailed description of adjuvants is available in a review by M.Z.I Khan et al. in Pharmaceutical Research, vol. 11, No. 1 5 (1994) pp2-11, and also in another review by Gupta et al., in Vaccine, Vol. 13, No. 14, pp1263-1276 (1995) and in WO 99/24578. Preferred adjuvants include QuilA™, QS21™, Alhydrogel™ and Adjuphos™.

10 Pharmaceutical compositions of the invention may be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermoabsorption, or buccal or oral.

The term "pharmaceutical composition" is also meant to include 15 antibodies. In accordance with the present invention, there is also provided the use of one or more antibodies having binding specificity for the polypeptides of the present invention for the treatment or prophylaxis of streptococcal infection and/or diseases and symptoms mediated by streptococcal infection.

20

Pharmaceutical compositions of the invention are used for the prophylaxis or treatment of streptococcal infection and/or diseases and symptoms mediated by streptococcal infection as described in Manual of Clinical Microbiology, P.R. Murray (Ed, 25 in chief), E.J. Baron, M.A. Pfaller, F.C. Tenover and R.H. Tenover. ASM Press, Washington, D.C. seventh edition, 1999, 1773p.

In one embodiment, pharmaceutical compositions of the present 30 invention are used for the prophylaxis or treatment of sepsis, meningitis, pneumonia, cellulitis, osteomyelitis, septic arthritis, endocarditis, epiglottitis.

In one embodiment, pharmaceutical compositions of the present 35 invention are used for the prophylaxis or treatment of mild urinary tract infection to life-threatening sepsis and meningitis, including also osteomyelitis, endocarditis, amniotitis, endometritis, wound infections (postcesarean and postepisiotomy), cellulitis, fasciitis.

40

In one embodiment, pharmaceutical compositions of the present invention are used for the prophylaxis or treatment of primary bacteremia but also skin of soft tissue infection, pneumonia, urosepsis, endocarditis, peritonitis, meningitis, empyema. Skin
5 of soft tissue infections include cellulitis, infected peripheral ulcers, osteomyelitis, septic arthritis and decubiti or wound infections.

In one embodiment, pharmaceutical compositions of the invention
10 are used for the treatment or prophylaxis of Streptococcus infection and/or diseases and symptoms mediated by Streptococcus infection, in particular group B Streptococcus (GBS or S.agalactiae), group A Streptococcus (Streptococcus pyogenes), S.pneumoniae, S.dysgalactiae, S.uberis, S.nocardia as well as
15 Staphylococcus aureus. In a further embodiment, the Streptococcus infection is group B Streptococcus (GBS or S.agalactiae).

In a further embodiment, the invention provides a method for
20 prophylaxis or treatment of Streptococcus infection in a host susceptible to Streptococcus infection comprising administering to said host a therapeutic or prophylactic amount of a composition of the invention.

25 In a further embodiment, the invention provides a method for prophylaxis or treatment of GBS infection in a host susceptible to GBS infection comprising administering to said host a therapeutic or prophylactic amount of a composition of the invention.

30

In a particular embodiment, pharmaceutical compositions are administered to those hosts at risk of Streptococcus infection such as infants, elderly and immunocompromised hosts.

35 As used in the present application, the term "host" includes animals. In a further embodiment, the animals are mammals. In a further embodiment, the animals are dairy herds. In a further embodiment, the mammal is human. In a further embodiment, the host is a pregnant woman. In a further embodiment, the host is a

non-pregnant woman. In a further embodiment, the host is a neonate or an infant.

Pharmaceutical compositions are preferably in unit dosage form of about 0.001 to 100 µg/kg (antigen/body weight) and more preferably 0.01 to 10 µg/kg and most preferably 0.1 to 1 µg/kg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

10 Pharmaceutical compositions are preferably in unit dosage form of about 0.1 µg to 10 mg and more preferably 1µg to 1 mg and most preferably 10 to 100 µg 1 to 3 times with an interval of about 1 to 6 week intervals between immunizations.

15 According to another aspect, there are provided polynucleotides encoding polypeptides characterized by the amino acid sequence comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

20 In one embodiment, polynucleotides are those illustrated in SEQ ID No: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 which may include the open reading frames (ORF), encoding the polypeptides of the invention.

25 It will be appreciated that the polynucleotide sequences illustrated in the figures may be altered with degenerate codons yet still encode the polypeptides of the invention. Accordingly the present invention further provides polynucleotides which hybridize to the polynucleotide sequences herein above described
30 (or the complement sequences thereof) having 70% identity between sequences. In one embodiment, at least 80% identity between sequences. In one embodiment, at least 85% identity between sequences. In one embodiment, at least 90% identity between sequences. In one embodiment, at least 95% identity. In
35 a further embodiment, more than 97% identity.

In a further embodiment, polynucleotides are hybridizable under stringent conditions.

Suitable stringent conditions for hybridization can be readily determined by one of skilled in the art (see for example Sambrook et al., (1989) Molecular cloning : A Laboratory Manual, 5 2nd ed, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology, (1999) Edited by Ausubel F.M. et al., John Wiley & Sons, Inc., N.Y.).

"Suitable stringent conditions", as used herein, means, for 10 example, incubating a blot overnight (e.g., at least 12 hours) with a long polynucleotide probe in a hybridization solution containing, e.g., about 5X SSC, 0.5% SDS, 100 µg/ml denatured salmon sperm DNA and 50% formamide, at 42°C. Blots can be washed at high stringency conditions that allow, e.g., for less 15 than 5% bp mismatch (e.g., wash twice in 0.1X SSC and 0.1% SDS for 30 min at 65°C), thereby selecting sequences having, e.g., 95% or greater sequence identity.

Other non-limiting examples of suitable stringent conditions include a final wash at 65°C in aqueous buffer containing 30 mM 20 NaCl and 0.5% SDS. Another example of suitable stringent conditions is hybridization in 7% SDS, 0.5 M NaPO₄, pH 7, 1 mM EDTA at 50°C, e.g., overnight, followed by one or more washes with a 1% SDS solution at 42°C. Whereas high stringency washes can allow for less than 5% mismatch, reduced or low stringency 25 conditions can permit up to 20% nucleotide mismatch. Hybridization at low stringency can be accomplished as above, but using lower formamide conditions, lower temperatures and/or lower salt concentrations, as well as longer periods of incubation time.

30

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- 35 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- 5 (b) the complement of a DNA sequence encoding a polypeptide;

wherein said polypeptide comprises SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20.

10 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a
- 15 polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

20 In a further embodiment, the present invention provides polynucleotides that hybridize under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
- (b) the complement of a DNA sequence encoding a
- 25 polypeptide;

wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18 or 20.

30 In a further embodiment, polynucleotides are those encoding polypeptides of the invention illustrated in SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.

In a further embodiment, polynucleotides are those illustrated
35 in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 encoding polypeptides of the invention or fragments or analogs thereof.

In a further embodiment, polynucleotides are those encoding polypeptides of the invention illustrated in SEQ ID NO: 2, 4, 6,
40 8, 10, 12, 14, 16, 18, 20.

In a further embodiment, polynucleotides are those illustrated in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 encoding polypeptides of the invention.

5

As will be readily appreciated by one skilled in the art, polynucleotides include both DNA and RNA.

The present invention also includes polynucleotides complementary to the polynucleotides described in the present application.

In a further aspect, polynucleotides encoding polypeptides of the invention, or fragments, analogs or derivatives thereof, may be used in a DNA immunization method. That is, they can be incorporated into a vector which is replicable and expressible upon injection thereby producing the antigenic polypeptide in vivo. For example polynucleotides may be incorporated into a plasmid vector under the control of the CMV promoter which is functional in eukaryotic cells. Preferably the vector is injected intramuscularly.

According to another aspect, there is provided a process for producing polypeptides of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host cell and recovering the expressed polypeptide product. Alternatively, the polypeptides can be produced according to established synthetic chemical techniques i.e. solution phase or solid phase synthesis of oligopeptides which are ligated to produce the full polypeptide (block ligation).

General methods for obtention and evaluation of polynucleotides and polypeptides are described in the following references: Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York; PCR Cloning Protocols, from Molecular Cloning to Genetic Engineering, Edited by White B.A., Humana Press, Totowa, New Jersey, 1997, 490 pages; Protein Purification, Principles

and Practices, Scopes R.K., Springer-Verlag, New York, 3rd Edition, 1993, 380 pages; Current Protocols in Immunology, Edited by Coligan J.E. et al., John Wiley & Sons Inc., New York.

5 For recombinant production, host cells are transfected with vectors which encode the polypeptides of the invention, and then cultured in a nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes. Suitable vectors are those that are viable and replicable
10 in the chosen host and include chromosomal, non-chromosomal and synthetic DNA sequences e.g. bacterial plasmids, phage DNA, baculovirus, yeast plasmids, vectors derived from combinations of plasmids and phage DNA. The polypeptide sequence may be incorporated in the vector at the appropriate site using
15 restriction enzymes such that it is operably linked to an expression control region comprising a promoter, ribosome binding site (consensus region or Shine-Dalgarno sequence), and optionally an operator (control element). One can select individual components of the expression control region that are
20 appropriate for a given host and vector according to established molecular biology principles (Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor, N.Y., 1989; Current Protocols in Molecular Biology, Edited by Ausubel F.M. et al., John Wiley and Sons, Inc. New York). Suitable promoters
25 include but are not limited to LTR or SV40 promoter, E.coli lac, tac or trp promoters and the phage lambda P_L promoter. Vectors will preferably incorporate an origin of replication as well as selection markers i.e. ampicillin resistance gene. Suitable bacterial vectors include pET, pQE70, pQE60, pQE-9, pD10
30 phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A, ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 and eukaryotic vectors pBlueBacIII, pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG and pSVL. Host cells may be bacterial i.e. E.coli, Bacillus subtilis, Streptomyces; fungal i.e.
35 Aspergillus niger, Aspergillus nidulins; yeast i.e. Saccharomyces or eukaryotic i.e. CHO, COS.

Upon expression of the polypeptide in culture, cells are typically harvested by centrifugation then disrupted by physical
40 or chemical means (if the expressed polypeptide is not secreted

into the media) and the resulting crude extract retained to isolate the polypeptide of interest. Purification of the polypeptide from culture media or lysate may be achieved by established techniques depending on the properties of the polypeptide i.e. using ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography. Final purification may be achieved using HPLC.

The polypeptides may be expressed with or without a leader or secretion sequence. In the former case the leader may be removed using post-translational processing (see US 4,431,739; US 4,425,437; and US 4,338,397) or be chemically removed subsequent to purifying the expressed polypeptide.

According to a further aspect, the polypeptides of the invention may be used in a diagnostic test for Streptococcus infection, in particular group B Streptococcus infection.

Several diagnostic methods are possible, for example detecting Streptococcus organism in a biological sample, the following procedure may be followed:

25

- a) obtaining a biological sample from a host;
- b) incubating an antibody or fragment thereof reactive with a Streptococcal polypeptide of the invention with the biological sample to form a mixture; and
- 30 c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of Streptococcus.

Alternatively, a method for the detection of antibody specific to a Streptococcus antigen and in particular a group B Streptococcus antigen in a biological sample containing or suspected of containing said antibody may be performed as follows:

- a) obtaining a biological sample from a host;

- b) incubating one or more Streptococcal polypeptides of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to Streptococcus.

One of skill in the art will recognize that this diagnostic test may take several forms, including an immunological test such as an enzyme-linked immunosorbent assay (ELISA), a radioimmunoassay or a latex agglutination assay, essentially to determine whether antibodies specific for the polypeptide are present in an organism.

The DNA sequences encoding polypeptides of the invention may also be used to design DNA probes for use in detecting the presence of Streptococcus in a biological sample suspected of containing such bacteria. The detection method of this invention comprises:

- a) obtaining the biological sample from a host;
- b) incubating one or more DNA probes having a DNA sequence encoding a polypeptide of the invention or fragments thereof with the biological sample to form a mixture; and
- c) detecting specifically bound DNA probe in the mixture which indicates the presence of Streptococcus bacteria.

The DNA probes of this invention may also be used for detecting circulating Streptococcus i.e. Streptococcus nucleic acids in a sample, for example using a polymerase chain reaction, as a method of diagnosing Streptococcus infections. The probe may be synthesized using conventional techniques and may be immobilized on a solid phase, or may be labelled with a detectable label. A preferred DNA probe for this application is an oligomer having a sequence complementary to at least about 6 contiguous nucleotides of the Streptococcus polypeptides of the invention.

Another diagnostic method for the detection of Streptococcus in a host comprises:

- a) labelling an antibody reactive with a polypeptide of the invention or fragment thereof with a detectable label;
- b) administering the labelled antibody or labelled fragment to the host; and
- 5 c) detecting specifically bound labelled antibody or labelled fragment in the host which indicates the presence of Streptococcus.

A further aspect of the invention is the use of the
10 Streptococcus polypeptides of the invention as immunogens for the production of specific antibodies for the diagnosis and in particular the treatment of Streptococcus infection. Suitable antibodies may be determined using appropriate screening methods, for example by measuring the ability of a particular
15 antibody to passively protect against Streptococcus infection in a test model. One example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigen-binding fragment thereof and may belong to any immunoglobulin class. The antibody or fragment may be of
20 animal origin, specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment. The term recombinant antibody or antibody fragment means antibody or antibody
25 fragment which was produced using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the Streptococcus polypeptides but is preferably specific for one.

30

A further aspect of the invention is the use of the antibodies directed to the polypeptides of the invention for passive immunization. One could use the antibodies described in the present application. Suitable antibodies may be determined using
35 appropriate screening methods, for example by measuring the ability of a particular antibody to passively protect against Streptococcus infection in a test model. One example of an animal model is the mouse model described in the examples herein. The antibody may be a whole antibody or an antigen-
40 binding fragment thereof and may belong to any immunoglobulin

class. The antibody or fragment may be of animal origin, specifically of mammalian origin and more specifically of murine, rat or human origin. It may be a natural antibody or a fragment thereof, or if desired, a recombinant antibody or antibody fragment. The term recombinant antibody or antibody fragment means antibody or antibody fragment which was produced using molecular biology techniques. The antibody or antibody fragments may be polyclonal, or preferably monoclonal. It may be specific for a number of epitopes associated with the Streptococcus polypeptides but is preferably specific for one.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method or system such as direct injection of plasmid DNA into muscles [Wolf et al. H M G (1992) 1: 363; Turnes et al., Vaccine (1999), 17 : 2089; Le et al., Vaccine (2000) 18 : 1893; Alves et al., Vaccine (2001) 19 : 788], injection of plasmid DNA with or without adjuvants [Ulmer et al., Vaccine (1999) 18: 18; MacLaughlin et al., J. Control Release (1998) 56: 259; Hartikka et al., Gene Ther. (2000) 7: 1171-82; Benvenisty and Reshef, PNAS USA (1986) 83:9551; Singh et al., PNAS USA (2000) 97: 811], targeting cells by delivery of DNA complexed with specific carriers [Wa et al., J Biol Chem (1989) 264: 16985; Chaplin et al., Infect. Immun. (1999) 67: 6434], injection of plasmid complexed or encapsulated in various forms of liposomes [Ishii et al., AIDS Research and Human Retroviruses (1997) 13: 142; Perrie et al., Vaccine (2001) 19: 3301], administration of DNA with different methods of bombardment [Tang et al., Nature (1992) 356: 152; Eisenbraun et al., DNA Cell Biol (1993) 12: 791; Chen et al., Vaccine (2001) 19: 2908], and administration of DNA with lived vectors [Tubulekas et al., Gene (1997) 190: 191; Pushko et al., Virology (1997) 239: 389; Spreng et al. FEMS (2000) 27: 299; Dietrich et al., Vaccine (2001) 19: 2506].

In a further aspect, the invention provides a method for prophylactic or therapeutic treatment of Streptococcus infection in a host susceptible to Streptococcus infection comprising administering to the host a prophylactic or therapeutic amount of a pharmaceutical composition of the invention.

In a further embodiment, the invention provides the use of a pharmaceutical method for the prophylactic or therapeutic treatment of streptococcal bacterial infection in a host susceptible to streptococcal infection comprising administering 5 to said host a therapeutic or prophylactic amount of a composition of the invention.

In a further embodiment, the invention provides a kit comprising a polypeptide of the invention for detection or diagnosis of 10 streptococcal infection.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. 15 All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not 20 intended to be limiting.

EXAMPLE 1

25 This example describes the cloning of truncated sip gene products by polymerase chain reaction (PCR) and the expression of truncated molecules.

Fragments of Group B streptococcal sip (SEQ ID NO: 42 from PCT 30 WO 99/42588) gene were amplified by PCR (DNA Thermal Cycler GeneAmp PCR system 2400 Perkin Elmer) from genomic DNA of serotype I a/c Group B streptococcal strain C388/90 using pairs of oligonucleotide primers that contained base extensions for the addition of restriction sites and methionine (Table 1). The 35 methionine was added for C-terminal and internal truncated Sip polypeptide. PCR products were purified from agarose gel using a QIAquick gel extraction kit from QIAGEN following the manufacturer's instructions, and digested with restriction endonucleases. The pET vector (Novagen, Madison, WI) was 40 digested with the same endonucleases and purified from agarose

gel using a QIAquick gel extraction kit from QIAGEN. The digested PCR products were ligated to one of the following linearized pET expression plasmid, pET21 or pET32. The ligated product was transformed into *E. coli* strain DH5 α [F ϕ 80d*lacZ* Δ M15 Δ (*lacZYA-argF*)U169 *endA1 recA1 hsdR17(r_k⁻m_k⁺) deoR thi-1 phoA supE44 λ *gyrA96 relA1*] (Gibco BRL, Gaithersburg, MD) according to the manufacturer's recommendations. Recombinant pET plasmids (rpET) containing *sip* gene fragments were purified using a QIAGEN plasmid kit and their DNA insert was sequenced (Taq Dye*

10 Deoxy Terminator Cycle Sequencing kit, ABI, Foster City, CA). Each of the resultant plasmid constructs was used to transform by electroporation (Gene Pulser II apparatus, BIO-RAD Labs, Mississauga, Ontario, Canada) *E. coli* strain BL21(DE3) (F ϕ *ompT hsdS_B(r_B⁻m_B⁻) gal dcm* (DE3)) or AD494(DE3) [Δ *ara-leu7697* Δ *lacX74*

15 Δ *phoA PvuII phoR* Δ *malF3* F' [*lac⁺(lacI^q) pro*] *trxB::Kan* (DE3)] (Novagen). In these strains of *E. coli*, the T7 promoter controlling expression of the recombinant polypeptide is specifically recognized by the T7 RNA polymerase (present on the λ DE3 prophage) whose gene is under the control of the *lac*

20 promoter which is inducible by IPTG. The transformants were grown at 37°C with agitation at 250 rpm in LB broth (peptone 10g/L, yeast extract 5g/L, NaCl 10g/L) containing 100 μ g of carbenicillin (Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada) per ml until the A₆₀₀ reached a value of 0.6. In order to

25 induce the production of Group B streptococcal truncated Sip recombinant polypeptides, the cells were incubated for 3 additional hours in the presence of IPTG at a final concentration of 1 mM. Induced cells from a 500 ml culture were pelleted by centrifugation and frozen at -80°C. The expressed

30 recombinant polypeptides were purified from supernatant fractions obtained from centrifugation of sonicated IPTG-induced *E. coli* cultures using a His-Bind metal chelation resin (QIAGEN, Chatsworth, CA). The gene products generated are listed in the Table 2. The quantities of recombinant polypeptides obtained

35 from the soluble fraction of *E. coli* was estimated by MicroBCA (Pierce, Rockford, Illinois).

Table 1. List of PCR oligonucleotide primers

Primer	Restriction sites	Sequence 5' - 3'	SEQ ID No
DMAR41	<i>NcoI</i>	catgccatggcagggctccaacctcatgtt	21
DMAR54	<i>NcoI</i>	catgccatggcagctaataaacaggtatcaacagc	22
DMAR55	<i>XhoI</i>	gaaactcgagtgcattttcaggatgtgcagctac	23
DMAR207	<i>BglIII</i>	gccagatctgggtataaaaccaagcacttgg	24
DMAR208	<i>BglIII</i>	gccagatctgggtatctggcaacaaaagttttac	25
DMAR1451	<i>HindIII</i>	cgggaagcttattattttgttaaatgatacgtgaaca	26
DMAR1452	<i>NcoI</i>	caagccatgggtatgacaccagaagcagcaaca	27
DMAR1453	<i>XhoI</i>	accgctcgagtttggttaaatgatacgtgaacatgggtca	28
DMAR1454	<i>NcoI</i>	ccatccatgggtcagtcagtcacaacagtatcaccag	29
DMAR1455	<i>NcoI</i>	aatgccatgggtcctgtgactacgacttcaacagc	30
DMAR1456	<i>XhoI</i>	aactcgaggctgctaaacctttaccatgatcacct	31
DMAR1457	<i>NdeI</i>	atgggaattccatatgaaaatgaataaaaaggtactat tgacatc	32
DMAR1458	<i>XhoI</i>	atagctcgagtgcagtcgtgagttggtttaacttcc	33

Table 2. Lists of truncated *sip* gene products generated from GBS 5 strain C388/90

Polypeptide designation	PCR-primer sets	Identification (encoded amino acids)	Cloning vector
Δ Sip-1	DMAR1457-DMAR1458	Sip N'end (1-214)	pET-21a(+)
Δ Sip-2	DMAR1453-DMAR1454	Sip C'end (215-434)	pET-21d(+)
Δ Sip-3	DMAR1452-DMAR1453	Sip C'end (146-434)	pET-21d(+)
Δ Sip-4	DMAR1453-DMAR1455	Sip C'end (272-434)	pET-21d(+)
Δ Sip-5	DMAR1456-DMAR1457	Sip N'end (1-360)	pET-21a(+)
Δ Sip-6	DMAR1453-DMAR54	Sip N'end (184-434)	pET-21d(+)
Δ Sip-7	DMAR1452-DMAR55	Sip internal (146-322)	pET-21d(+)
Δ Sip-8	DMAR1453-DMAR41	Sip C'end (322-434)	pET-21d(+)

Δ Sip-9	DMAR207-DMAR1451	Sip C'end (366-434)	pET-32a(+)
Δ Sip-10	DMAR208-DMAR1451	Sip C'end (391-434)	pET-32a(+)

EXAMPLE 2

5 This example illustrates the reactivity of the His-tagged truncated Sip recombinant polypeptides with antibodies present in human sera.

As shown in Table 3, Δ Sip-2 (215-434), Δ Sip-3 (146-434), and
 10 Δ Sip-4 (272-434) His-tagged recombinant polypeptides were best recognized in immunoblots by the antibodies present in the pool of human sera. This is an important result since it clearly indicates that humans which are normally in contact with GBS do develop antibodies that are specific to the C-terminal portion
 15 of the polypeptide (aa 215-434). These particular human antibodies might be implicated in the protection against GBS infection.

Table 3. Reactivity in immunoblots of antibodies present in
 20 human sera with truncated Sip polypeptides.

Purified recombinant polypeptide I.D. ¹	Reactivity with human sera ²
Sip (1-434)	+++
Δ Sip-1 (1-214)	+
Δ Sip-2 (215-434)	+++
Δ Sip-3 (146-434)	+++
Δ Sip-4 (272-434)	++
Δ Sip-5 (1-360)	+

¹His-tagged recombinant polypeptides produced and purified as described in Example 1 were used to perform the immunoblots.

²Sera collected from humans were pooled and diluted 1/500 to
 25 perform the immunoblots.

EXAMPLE 3

This example illustrates the binding at the surface of intact GBS cells of antibodies directed against truncated Sip polypeptides.

Bacterial cells were grown to early exponential phase in Todd-Hewitt broth (THB: Difco Laboratories, Detroit, Mich.) and the OD_{600nm} was adjusted with THB to 0.15 (corresponding to ~10⁸ CFU/ml). Ten µl of mouse truncated Sip-specific or control sera were added to 1 ml of the bacterial suspension. The tubes containing the bacterial and sera suspensions were incubated for 2 h at 4°C under gentle rotation. Samples were washed 3 times in blocking buffer [phosphate-buffered saline (PBS) containing 2% (wt/vol) bovine serum albumin (BSA: Sigma Chemical Co., St. Louis, Mo.)], and then 1 ml of goat fluorescein (FITC)-conjugated anti-mouse IgG + IgM (Jackson ImmunoResearch Laboratories, Mississauga, Ontario, Canada) diluted in blocking buffer was added. After a further incubation of 60 min at room temperature, samples were washed 3 times in blocking buffer and fixed with 0.3 % formaldehyde in PBS buffer for 18 h at 4°C. Cells were washed 2 times in PBS buffer and resuspended in 0.5 ml of PBS buffer. Cells were kept in the dark at 4°C until being analyzed by flow cytometry (Epics® XL; Beckman Coulter Inc., Fullerton, Calif.).

Flow cytometric analysis revealed that ΔSip-2 (215-434), ΔSip-3 (146-434), and ΔSip-4 (272-434)-specific antibodies efficiently recognized their corresponding surface-exposed epitopes on the homologous (C388/90) GBS strain tested (Table 4). It was determined that more than 90 % of the 10,000 GBS cells analyzed were labeled with the antibodies present in these sera. In addition, antibodies present in the pool of ΔSip-2 (215-434), ΔSip-3 (146-434), and ΔSip-4 (272-434)-specific sera attached at the surface of the serotype III GBS strain NCS 954 (Table 4). It was also determined that more than 80% of the 10,000 cells of

this strain were labeled by the specific antibodies. These observations clearly demonstrate that the C-terminal portion of the Sip polypeptide is accessible at the surface, where it can be easily recognized by antibodies. Anti-GBS antibodies were shown to play an important role in the protection against GBS infection. Indeed, we have demonstrated that Sip-specific antibodies efficiently cross the transplacental barrier and thus confer protective immunity against GBS infections (Martin et al. Abstr. 101th Gen. Meet. Am. Soc. Microbiol. 2001).

10

Table 4. Evaluation of the attachment of truncated Sip-specific antibodies at the surface of intact GBS cells.

Serum identification ¹	Strain C388/90 (I a/c)		Strain NCS 954 (III)	
	% of labeled cells ²	Fluorescence Index ³	% of labeled cells	Fluorescence Index
Pool of Δ Sip-1-specific sera	5.1	1.2	10.0	1.6
Pool of Δ Sip-2-specific sera	95.6	18.7	87.7	14.2
Pool of Δ Sip-3-specific sera	96.0	19.4	87.7	13.3
Pool of Δ Sip-4-specific sera	94.2	17.2	84.2	11.6
Pool of Δ Sip-5-specific sera	21.6	2.2	5.2	1.3
Pool of positive control serum ⁴	95.4	24.1	85.4	12.3
Pool of negative control sera ⁵	1.0	1.0	1.0	1.0

¹The mice were injected subcutaneously three times at three-week intervals with 20 μ g of purified recombinant polypeptides mixed with 20 μ g of QuilA adjuvant. The sera were diluted 1/100.

²% of labeled cells out of the 10,000 cells analyzed.

³The fluorescence index was calculated as the median fluorescence value obtained after labeling the cells with an immune serum divided by the fluorescence value obtained for a control mouse serum. A fluorescence value of 1 indicated that there was no binding of antibodies at the surface of intact GBS cells.

⁴Serum obtained from a mouse immunized with 20 µg of purified Sip polypeptide from GBS strain C388/90 was diluted 1/100 and used as a positive control for the assay.

⁵Sera collected from unimmunized or sham-immunized mice were pooled, diluted 1/100, and used as negative controls for this assay.

EXAMPLE 4

This example illustrates the protection of mice against fatal Group B streptococcal infection induced by immunization with purified truncated Sip recombinant polypeptides.

Groups of 8 female CD-1 mice (Charles River) were immunized subcutaneously three times at three-week intervals with 20 µg of truncated Sip polypeptides that were produced and purified as described in Example 1 in presence of 20 µg of QuilA adjuvant (Cedarlane Laboratories Ltd, Hornby, Ontario, Canada). The control mice were injected with QuilA adjuvant alone in PBS. Blood samples were collected from the orbital sinus on day 1, 21, and 42 prior to each immunization and 14 days (day 56) following the third injection. One weeks later the mice were challenged with approximately 3×10^5 CFU of the Group B streptococcal strain C388/90 (Ia/c). Samples of the Group B streptococcal challenge inoculum were plated on blood agar plates to determine the CFU and to verify the challenge dose. Deaths were recorded for a period of 7 days. More than 60% of the mice immunized with either ΔSip-2 (215-434), ΔSip-3 (146-434), ΔSip-4 (272-434), and ΔSip-6 (184-434) recombinant polypeptides were protected against a lethal challenge with GBS. On the contrary, immunization of mice with adjuvant only, ΔSip-1 (1-214), or ΔSip-5 (1-360) did not confer such protection (Table 5). The survival rate determined for the groups of mice immunized with ΔSip-2 (215-434), ΔSip-3 (146-434), ΔSip-4 (272-434), and

Δ Sip-6 (184-434) were shown to be statistically different from the control group by the Fisher's exact test.

5 Table 5. Ability of recombinant truncated Sip polypeptides to elicit protection against GBS strain C388/90 (I a/c)

Groups	No. mice surviving	% survival
Δ Sip-1 (1-214)	0/5	0
Δ Sip-2 (215-434)	3/5	60*
Δ Sip-3 (146-434)	3/5	60*
Δ Sip-4 (272-434)	3/4	75*
Δ Sip-5 (1-360)	2/5	40
Δ Sip-6 (184-434)	7/8	88*
QuilA	0/5	0

* Fisher's exact test.; $p < 0.05$

EXAMPLE 5

10

This example describes the isolation of monoclonal antibodies (Mabs) and the use of these Mabs to characterize the Sip polypeptide epitopes.

15 Female CD1 mice (Charles River) were immunized subcutaneously with Δ sip-3 gene product from GBS strain C388/90 in presence of 20 μ g of QuilA adjuvant (Cedarlane Laboratories Ltd, Hornby, Canada). A group of mice were immunized three times at three-week intervals with 20 μ g of affinity purified Δ Sip-3
 20 polypeptide. Three to four days before fusion, mice were injected intravenously with 10 μ g of the respective antigen suspended in PBS alone. Hybridomas were produced by fusion of spleen cells with non-secreting SP2/0 myeloma cells as previously described by Hamel et al. [J. Med. Microbiol., 23,
 25 pp163-170 (1987)]. Culture supernatants of hybridomas were initially screened by enzyme-linked-immunoassay according to the procedure described by Brodeur et al. (2000) using plates coated

with preparations of purified recombinant polypeptides or suspensions of heat-killed GBS cells. Positive hybridomas selected on the basis of ELISA reactivity with a variety of antigens were then cloned by limiting dilutions, expanded and 5 frozen.

Hybridomas were tested by ELISA and Western immunoblotting against sip gene products, and by cytofluorometry assay against GBS strain C388/90 (serotype Ia/c) in order to characterize the 10 epitopes recognized by the Mabs. The results obtained from the immunoreactivity studies of the Mabs (Table 6 and Table 7) are in agreement with the surface accessibility obtained with truncated Sip polypeptides. Indeed, the most accessible Mabs recognized the C-terminal region (215-434) of the Sip 15 polypeptide. Particularly, data revealed the presence of at least four distinct surface-exposed and potentially protective epitopes on the Sip polypeptide. These regions were determined to be located to amino acids 215-272, 272-322, 360-366, and 391-434. On the contrary, epitopes located at the N-terminal portion 20 comprising amino acids 1 to 214 were internal and not accessible to antibodies.

Table 6. Reactivity of Sip-immunoreactive Mabs with a panel of sip gene products.

Mabs	Sip	Δ Sip-1 (1-214aa)	Δ Sip-2 (215-434aa)	Δ Sip-3 (146-434aa)	Δ Sip-4 (272-434aa)	Δ Sip-5 (1-360aa)	Δ Sip-6 (184-434aa)	Δ Sip-7 (146-322aa)	Δ Sip-8 (322-434aa)	Δ Sip-9 (366-434aa)	Δ Sip-10 (391-434aa)
1F7	+	-	+	+	+	-	+	-	+	-	-
3B7	+	-	+	+	+	-	+	-	+	+	+
4F2	+	-	+	+	+	-	+	-	+	-	-
5E5	+	+	-	+	-	+	+	+	-	NT*	NT
5F11	+	-	+	+	+	-	+	-	+	-	-
6F3	+	-	+	+	+	+	+	+	-	NT	NT
8E3	+	-	+	+	+	+	+	+	-	NT	NT
8F6	+	+	-	+	-	+	-	+	-	NT	NT
9C7	+	-	+	+	+	-	+	-	+	-	-
11C9	+	-	+	+	+	+	+	+	-	NT	NT
11D2	+	-	+	+	+	-	+	-	+	-	-
11E10	+	-	+	+	+	-	+	-	+	-	-
12G10	+	-	+	+	-	+	+	+	-	NT	NT
13D12	+	-	+	+	+	-	+	-	+	+	+
14A2	+	-	+	+	+	-	+	-	+	+	+
14H4	+	-	+	+	+	-	+	-	+	+	+
14H8	+	-	+	+	+	-	+	-	+	-	-
17C10	+	+	-	+	-	+	-	+	-	NT	NT
18A8	+	-	+	+	+	-	+	-	+	+	+
18H10	+	-	+	+	+	-	+	-	+	-	-
20A2	+	-	+	+	-	+	+	+	-	NT	NT
20G5	+	-	+	+	+	-	+	-	+	-	-

*NT: not tested.

Table 7. Evaluation of Sip-immunoreactive Mabs attachment at the surface of intact GBS cells.

<u>Mabs</u>	Recognized epitope (aa)¹	% of labeled cells²	Fluorescence index³
17C10	146-184	0.7	1.6
8F6	146-184	1.1	1.8
5E5	184-215	5.7	1.9
12G10	215-272	42.1	7.1
20A2	215-272	1.1	1.8
6F3	272-322	25.6	4.9
8E3	272-322	28.6	5.2
11C9	272-322	39.7	5.8
1F7	360-366	78.9	7.5
4F2	360-366	97.9	7.2
5F11	360-366	43.1	2.2
9C7	360-366	93.8	6.1
11D2	360-366	87.1	11.9
11E10	360-366	45.8	2.3
14H8	360-366	90.8	4.8
18H10	360-366	98.0	8.4
20G5	360-366	96.5	6.9
3B7	391-434	98.3	10.4
13D12	391-434	90.0	10.4
14A2	391-434	98.4	10.8
14H4	391-434	97.5	10.0
18A8	391-434	97.7	11.7
Negative control Mab ⁴	-	1.5	1.0
Pool of positive control serum ⁵	-	98.7	25.0

¹Epitopes have been determined by the Mabs reactivity with truncated Sip polypeptides (see Table 6).

5

²% of labeled cells out of the 10,000 cells analyzed.

³The fluorescence index was calculated as the median fluorescence value obtained after labeling the cells with a Mab or immune serum divided by the fluorescence value obtained for a control Mab. A fluorescence value of 1 indicated that there was no binding of antibodies at the surface of intact GBS cells.

10

⁴Irrelevant Mab was not diluted and was used as negative controls for this assay.

- 5 ⁵Serum obtained from a mouse immunized with 20 µg of purified Sip polypeptide from GBS strain C388/90 was diluted 1/100 and was used as a positive control for the assay.

10 Example 6

This example illustrates the protection of mice against fatal Group B streptococcal infection induced by passive immunization with Sip-specific Mabs.

15

- The protective potential of Sip-specific Mabs to protect neonates against infection was evaluated by passive administration of semi-purified Mabs antibodies. Pregnant mice on day 16 of gestation were injected intravenously (i.v.) with
- 20 500 µl of semi-purified Mabs antibodies or partially purified rabbit Sip-specific antibodies. Six control pregnant mice received the same volume of semi-purified irrelevant Mab. The pups were challenged subcutaneously (s.c.) between 24 h to 48 h after birth with a lethal dose of $3-4 \times 10^4$ cfu from the serotype
- 25 Ia/c GBS strain C388/90. The survival data are presented in Table 8. Administration to pregnant of a combination of two Sip-specific Mabs, 6F3 and 11D2, protected 65% (15/23) of the pups against a lethal GBS challenge. Comparable survival of the pups was not observed when the pregnant mice received one Sip-
- 30 specific Mab.

Table 8. Passive protection of neonatal mice against challenge with serotype Ia/c GBS strain C388/90.

Treatment of dams (n) ¹	Survival in pups (%) ²
6F3 (5)	3/52 (6)
11D2 (2)	3/14 (21)
6F3-11D2 (2)	15/23 (65)
Rabbit anti-Sip serum (4)	37/38 (97)
Irrelevant Mab (6)	0/69 (0)

¹ A maximum volume of 500 µl of semi-purified antibodies were administered i.v. to pregnant mice on day 16 of gestation. When a combination of two Mabs was passively administered to the pregnant mice, 250 µl of each Mab were pooled together before injection.

² Number of survivors was followed for 7 days after challenge. The pups were challenged s.c. with 50 µl containing 3-4x10⁴ cfu from the serotype Ia/c GBS strain C388/90 between 24 to 48 h after birth.

What is claimed is:

1. An isolated polynucleotide comprising a polynucleotide chosen from:
 - (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (c) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (d) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (e) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (f) a polynucleotide comprising a sequence chosen from SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19 or fragments or analogs thereof;
 - (g) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e) or (f).
2. An isolated polynucleotide comprising a polynucleotide chosen from:
 - (a) a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8 or 10, 12, 14, 16, 18, 20;
 - (b) a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising

- a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8 or 10, 12, 14, 16, 18, 20;
- (c) a polynucleotide encoding a polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (d) a polynucleotide encoding a polypeptide capable of generating antibodies having binding specificity for a polypeptide comprising a sequence chosen from: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (e) a polynucleotide encoding an epitope bearing portion of a polypeptide comprising a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (f) a polynucleotide comprising a sequence chosen from SEQ ID Nos: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19;
 - (g) a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e) or (f).
3. The polynucleotide of claim 1, wherein said polynucleotide is DNA.
4. The polynucleotide of claim 2, wherein said polynucleotide is DNA.
5. The polynucleotide of claim 1, wherein said polynucleotide is RNA.
6. The polynucleotide of claim 2, wherein said polynucleotide is RNA.
7. The polynucleotide of claim 1 that hybridizes under stringent conditions to either
- (a) a DNA sequence encoding a polypeptide or
 - (b) the complement of a DNA sequence encoding a polypeptide;
- wherein said polypeptide comprises SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.
8. The polynucleotide of claim 2 that hybridizes under stringent conditions to either

- (a) a DNA sequence encoding a polypeptide or
 - (b) the complement of a DNA sequence encoding a polypeptide;
- wherein said polypeptide comprises SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20.
9. The polynucleotide of claim 1 that hybridizes under stringent conditions to either
- (a) a DNA sequence encoding a polypeptide or
 - (b) the complement of a DNA sequence encoding a polypeptide;
- wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof.
10. The polynucleotide of claim 2 that hybridizes under stringent conditions to either
- (a) a DNA sequence encoding a polypeptide or
 - (b) the complement of a DNA sequence encoding a polypeptide;
- wherein said polypeptide comprises at least 10 contiguous amino acid residues from a polypeptide comprising SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20.
11. A vector comprising the polynucleotide of claim 1, wherein said DNA is operably linked to an expression control region.
12. A vector comprising the polynucleotide of claim 2, wherein said DNA is operably linked to an expression control region.
13. A host cell transfected with the vector of claim 11.
14. A host cell transfected with the vector of claim 12.

15. A process for producing a polypeptide comprising culturing a host cell according to claim 13 under conditions suitable for expression of said polypeptide.
16. A process for producing a polypeptide comprising culturing a host cell according to claim 14 under condition suitable for expression of said polypeptide.
17. An isolated polypeptide comprising a polypeptide chosen from:
 - (h) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence comprising: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (i) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence comprising: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (j) a polypeptide comprising a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (k) a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (l) an epitope bearing portion of a polypeptide having a sequence chosen from SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof;
 - (m) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
 - (n) the polypeptide of (a), (b), (c), (d), (e), (f) or (g) wherein the secretory amino acid sequence is deleted.
18. An isolated polypeptide comprising a polypeptide chosen from:
 - (a) a polypeptide having at least 70% identity to a second polypeptide having an amino acid sequence comprising: SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;

- (b) a polypeptide having at least 95% identity to a second polypeptide having an amino acid sequence comprising: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (c) a polypeptide comprising a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (d) a polypeptide capable of generating antibodies having binding specificity for a polypeptide having a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (e) an epitope bearing portion of a polypeptide having a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20;
 - (f) the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;
 - (g) the polypeptide of (a), (b), (c), (d), (e), (f) or (g) wherein the secretory amino acid sequence is deleted.
19. A chimeric polypeptide comprising two or more polypeptides having a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20 or fragments or analogs thereof; provided that the polypeptides are linked as to form a chimeric polypeptide.
20. A chimeric polypeptide comprising two or more polypeptides having a sequence chosen from SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20; provided that the polypeptides are linked as to form a chimeric polypeptide.
21. A pharmaceutical composition comprising a polypeptide according to any one of claims 17 to 20 and a pharmaceutically acceptable carrier, diluent or adjuvant.
22. A method for prophylactic or therapeutic treatment of sepsis, meningitis, pneumonia, cellulitis, osteomyelitis, septic arthritis, endocarditis, epiglottitis. comprising administering to said host a prophylactic or therapeutic amount of a composition according to claim 21.

23. A method for prophylaxis or treatment of Streptococcus infection in a host susceptible to Streptococcus infection comprising administering to said host a therapeutic or prophylactic amount of a composition according to claim 21.
24. A method according to claim 22 wherein the host is an animal.
25. A method according to claim 22 wherein the host is chosen from a dairy herd.
26. A method according to claim 22 wherein the host is a human.
27. A method for diagnostic of Streptococcus infection in a host susceptible to Streptococcus infection comprising
 - (a) obtaining a biological sample from a host;
 - (b) incubating an antibody or fragment thereof reactive with a streptococcal polypeptide of any of the claims 17 to 20 with the biological sample to form a mixture; and
 - (c) detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of Streptococcus.
28. A method for detection of antibody specific to Streptococcus antigen in a biological sample comprising
 - (a) obtaining a biological sample from a host;
 - (b) incubating one or more streptococcal polypeptides according to any one of claims 17 to 20 or fragments thereof with the biological sample to form a mixture; and
 - (c) detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to Streptococcus.
29. Use of pharmaceutical method according to claim 22 for the prophylactic or therapeutic treatment of streptococcal bacterial infection in a host susceptible to streptococcal infection comprising administering to said host a

therapeutic or prophylactic amount of a composition according to claim 21.

30. Kit comprising a polypeptide according to any one of claims 17 to 20 for detection or diagnosis of streptococcal infection.

Figure 1 (SEQ ID NO: 1)

```

1  ATGAAAATGA  ATAAAAAGGT  ACTATTGACA  TCGACAATGG  CAGCTTCGCT  ATTATCAGTC
61  GCAAGTGTTT  AAGCACAAGA  AACAGATACG  ACGTGGACAG  CACGTACTGT  TTCAGAGGTA
121  AAGGCTGATT  TGGTAAAGCA  AGACAATAAA  TCATCATATA  CTGTGAAATA  TGGTGATACA
181  CTAAGCGTTA  TTTCAGAAGC  AATGTCAATT  GATATGAATG  TCTTAGCAAA  AATTAATAAC
241  ATTGACAGATA  TCAATCTTAT  TTATCCTGAG  ACAACACTGA  CAGTAACTTA  CGATCAGAAG
301  AGTCATACTG  CCACTTCAAT  GAAAATAGAA  ACACCAGCAA  CAAATGCTGC  TGGTCAAACA
361  ACAGCTACTG  TGGATTTGAA  AACCAATCAA  GTTCTCTGTT  CAGACCAAAA  AGTTTCTCTC
421  AATACAATTT  CGGAAGGTAT  GACACCAGAA  GCAGCAACAA  CGATTGTTTC  GCCAATGAAG
481  ACATATTCTT  CTGCGCCAGC  TTTGAAATCA  AAAGAAGTAT  TAGCACAAGA  GCAAGCTGTT
541  AGTCAAGCAG  CAGCTAATGA  ACAGGTATCA  ACAGCTCCTG  TGAAGTCGAT  TACTTCAGAA
601  GTTCCAGCAG  CTAAAGAGGA  AGTTAAACCA  ACTCAGACGT  CA

```

Figure 2 (SEQ ID NO: 2)

```

1  MKMNKKVLLT  STMAASLLSV  ASVQAQETDT  TWTARTVSEV  KADLVKQDNK  SSYTVKYGDT
61  LSVISEAMSI  DMNVLAKINN  IADINLIYPE  TTLTVTYDQK  SHTATSMKIE  TPATNAAGQT
121  TATVDLKTNQ  VSVADQKVSL  NTISEGMTPE  AATTIVSPMK  TYSSAPALKS  KEVLAQEQAQV
181  SQAAAANEQVS  TAPVKSITSE  VPAAKEEVKP  TQTS

```

Figure 3 (SEQ ID NO: 3)

```

1  GTCAGTCAGT  CAACAACAGT  ATCACCAGCT  TCTGTTGCCG  CTGAAACACC  AGCTCCAGTA
61  GCTAAAGTAG  CACCGGTAAG  AACTGTAGCA  GCCCCTAGAG  TGGCAAGTGT  TAAAGTAGTC
121  ACTCCTAAAG  TAGAACTGG  TGCATCACCA  GAGCATGTAT  CAGCTCCAGC  AGTTCCTGTG
181  ACTACGACTT  CAACAGCTAC  AGACAGTAAG  TTACAAGCGA  CTGAAGTTAA  GAGCGTTCCG
241  GTAGCACAAA  AAGCTCCAAC  AGCAACACCG  GTAGCACAA  CAGCTTCAAC  AACAAATGCA
301  GTAGCTGCAC  ATCCTGAAAA  TGCAGGGCTC  CAACCTCATG  TTGCAGCTTA  TAAAGAAAAA
361  GTAGCGTCAA  CTTATGGAGT  TAATGAATTC  AGTACATACC  GTGCAGGTGA  TCCAGGTGAT
421  CATGGTAAAG  GTTTAGCAGT  CGACTTTATT  GTAGGTAAAA  ACCAAGCACT  TGGTAATGAA
481  GTTGACACAGT  ACTCTACACA  AAATATGGCA  GCAAATAACA  TTTCATATGT  TATCTGGCAA
541  CAAAAGTTTT  ACTCAAATAC  AAATAGTATT  TATGGACCTG  CTAATACTTG  GAATGCAATG
601  CCAGATCGTG  GTGGCGTTAC  TGCCAACCAT  TATGACCATG  TTCACGTATC  ATTTAACAAA

```

Figure 4 (SEQ ID NO: 4)

```

1  VSQSTTVSPA  SVAAETPAPV  AKVAPVRTVA  APRVASVKVV  TPKVETGASP  EHVSAAPVPV
61  TTTSTATDSK  LQATEVKSVP  VAQKAPTATP  VAQPASTTNA  VAAHPENAGL  QPHVAAYKEK
121  VASTYGVNEF  STYRAGDPGD  HGKGLAVDFI  VGKNQALGNE  VAQYSTQNMA  ANNISYVIWQ
181  QKFYSNTNSI  YGPANTWNAM  PDRGGVTANH  YDHVHVSFNK

```

Figure 5 (SEQ ID NO: 5)

```

1 GGTATGACAC CAGAAGCAGC AACAAACGATT GTTTCGCCAA TGAAGACATA TTCTTCTGCG
61 CCAGCTTTTGA AATCAAAAAGA AGTATTAGCA CAAGAGCAAG CTGTTAGTCA AGCAGCAGCT
121 AATGAACAGG TATCAACAGC TCCTGTGAAG TCGATTACTT CAGAAGTTCC AGCAGCTAAA
181 GAGGAAGTTA AACCAACTCA GACGTCAGTC AGTCAGTCAA CAACAGTATC ACCAGCTTCT
241 GTTGCCGCTG AAACACCAGC TCCAGTAGCT AAAGTAGCAC CGGTAAGAAC TGTAGCAGCC
301 CCTAGAGTGG CAAGTGTTAA AGTAGTCACT CCTAAAGTAG AAAC TGGTGC ATCACCAGAG
361 CATGTATCAG CTCCAGCAGT TCCTGTGACT ACGACTTCAA CAGCTACAGA CAGTAAGTTA
421 CAAGCGACTG AAGTTAAGAG CGTTCGGGTA GCACAAAAAG CTCCAACAGC AACACCGGTA
481 GCACAACCAG CTTCAACAAC AAATGCAGTA GCTGCACATC CTGAAAATGC AGGGCTCCAA
541 CCTCATGTTG CAGCTTATAA AGAAAAAGTA GCGTCAACTT ATGGAGTTAA TGAATTCAGT
601 ACATACCGTG CAGGTGATCC AGGTGATCAT GGTAAAGGTT TAGCAGTCGA CTTTATTGTA
661 GGTAAAAACC AAGCACTTGG TAATGAAGTT GCACAGTACT CTACACAAAA TATGGCAGCA
721 AATAACATTT CATATGTTAT CTGGCAACAA AAGTTTACT CAAATACAA TAGTATTTAT
781 GGACCTGCTA ATACTTGGA TGCAATGCCA GATCGTGGT GC GTTACTGC CAACCATTAT
841 GACCATGTTC ACGTATCATT TAACAAA

```

Figure 6 (SEQ ID NO: 6)

```

1 GMTPEAATTI VSPMKTYSSA PALKSKEVLA QEQA VSQAAA NEQVSTAPVK SITSEVPAAK
61 EEVKPTQTSV SQSTTVSPAS VAAETPAPVA KVAPVRTVAA PRVASVKVVT PKVETGASPE
121 HVSAPAVPVT TTSTATDSKL QATEVKSVPV AQKAPTATPV AQPASTTNAV AAHPENAGLQ
181 PHVAAYKEKV ASTYGVNEFS TYRAGDPGDH GKGLAVDFIV GKNQALGNEV AQYSTQNMMA
241 NNISYVIWQQ KFYSNTNSIY GPANTWNAMP DRGGVTANHY DHVHVSFNK

```

Figure 7 (SEQ ID NO: 7)

```

1 GTTCCTGTGA CTACGACTTC AACAGCTACA GACAGTAAGT TACAAGCGAC TGAAGTTAAG
61 AGCGTTCCGG TAGCACAAAA AGCTCCAACA GCAACACCGG TAGCACAAACC AGCTTCAACA
121 ACAAATGCAG TAGCTGCACA TCCTGAAAAT GCAGGGCTCC AACCTCATGT TGCAGCTTAT
181 AAAGAAAAAG TAGCGTCAAC TTATGGAGTT AATGAATTCA GTACATACCG TGCAGGTGAT
241 CCAGGTGATC ATGGTAAAGG TTTAGCAGTC GACTTTATTG TAGGTAAAAA CCAAGCACTT
301 GGTAATGAAG TTGCACAGTA CTCTACACAA AATATGGCAG CAAATAACAT TTCATATGTT
361 ATCTGGCAAC AAAAGTTTTA CTCAAATACA AATAGTATTT ATGGACCTGC TAATACTTGG
421 AATGCAATGC CAGATCGTGG TGGCGTTACT GCCAACCAT TATGACCATGT TCACGTATCA
481 TTTAACAAA

```

Figure 8 (SEQ ID NO: 8)

```

1 VPVTTTSTAT DSKLQATEVK SVPVAQKAPT ATPVAQPAST TNAVAHPEN AGLQPHVAAY
61 KEKVASTYGV NEFSTYRAGD PGDHGKGLAV DFIVGKNQAL GNEVAQYSTQ NMAANNISYV
121 IWQQKFYSNT NSIYGPANTW NAMPDRGGVT ANHYDHVHVS FNK

```

Figure 9 (SEQ ID NO: 9)

```

1 ATGAAAATGA ATAAAAAGGT ACTATTGACA TCGACAATGG CAGCTTCGCT ATTATCAGTC
61 GCAAGTGTTT AAGCACAAGA AACAGATACG ACGTGGACAG CACGTACTGT TTCAGAGGTA
121 AAGGCTGATT TGGTAAAGCA AGACAATAAA TCATCATATA CTGTGAAATA TGGTGATACA
181 CTAAGCGTTA TTTCAGAAGC AATGTCAATT GATATGAATG TCTTAGCAAA AATTAATAAC
241 ATTGCAGATA TCAATCTTAT TTATCCTGAG ACAACACTGA CAGTAACTTA CGATCAGAAG
301 AGTCATACTG CCACTTCAAT GAAAATAGAA ACACCAGCAA CAAATGCTGC TGGTCAAACA
361 ACAGCTACTG TGGATTTGAA AACCAATCAA GTTTCCTGTTG CAGACCAAAA AGTTTCTCTC
421 AATACAATTT CGGAAGGTAT GACACCAGAA GCAGCAACAA CGATTGTTTC GCCAATGAAG
481 ACATATTCTT CTGCGCCAGC TTTGAAATCA AAAGAAGTAT TAGCACAAGA GCAAGCTGTT
541 AGTCAAGCAG CAGCTAATGA ACAGGTATCA ACAGCTCCTG TGAAGTCGAT TACTTCAGAA
601 GTTCCAGCAG CTAAAGAGGA AGTTAAACCA ACTCAGACGT CAGTCAGTCA GTCAACAACA
661 GTATCACCAG CTTCTGTTGC CGCTGAAACA CCAGCTCCAG TAGCTAAAGT AGCACCGGTA
721 AGAACTGTAG CAGCCCCTAG AGTGGCAAAG GTTAAAGTAG TCACTCCTAA AGTAGAAACT
781 GGTGCATCAC CAGAGCATGT ATCAGCTCCA GCAGTTCCTG TGAAGTCGAT TACTTCAGAA
841 ACAGACAGTA AGTTACAAGC GACTGAAGTT AAGAGCGTTC CGGTAGCACA AAAAGCTCCA
901 ACAGCAACAC CGGTAGCACA ACCAGCTTCA ACAACAAATG CAGTAGCTGC ACATCCTGAA
961 AATGCAGGGC TCCAACCTCA TGTTGCAGCT TATAAAGAAA AAGTAGCGTC AACTTATGGA
1021 GTTAATGAAT TCAGTACATA CCGTGCAGGT GATCCAGGTG ATCATGGTAA AGGTTTAGCA

```

Figure 10 (SEQ ID NO: 10)

```

1 MKMNNKVLLT STMAASLLSV ASVQAQETDT TWTARTVSEV KADLVKQDNK SSYTVKYGDT
61 LSVISEAMSI DMNVLAKINN IADINLIYPE TTLTVTYDQK SHTATSMKIE TPATNAAGQT
121 TATVDLKTNQ VSVADQKVSL NTISEGMTPE AATTIVSPMK TYSSAPALKS KEVLAQEQAV
181 SQAAAANEQVS TAPVKSITSE VPAAKEEVKP TQTSVSQSTT VSPASVAAET PAPVAKVAPV
241 RTVAAPRVAS VKVVT PKVET GASPEHVSAP AVPVTTTSTA TDSKLQATEV KSVPVQAQAP
301 TATPVAQPAS TTNAAVAHPE NAGLQPHVAA YKEKVASTYG VNEFSTYRAG DPGDHGKGLA

```

Figure 11 (SEQ ID NO: 11)

```

1 GCAGCTAATG AACAGGTATC AACAGCTCCT GTGAAGTCGA TTACTTCAGA AGTTCAGCA
61 GCTAAAGAGG AAGTTAAACC AACTCAGACG TCAGTCAGTC AGTCAACAAC AGTATCACCA
121 GCTTCTGTTG CCGCTGAAAC ACCAGCTCCA GTAGCTAAAG TAGCACCGGT AAGAACTGTA
181 GCAGCCCCTA GAGTGGCAAG TGTTAAAGTA GTCACCTCTA AAGTAGAAAC TGGTGCATCA
241 CCAGAGCATG TATCAGCTCC AGCAGTTCCT GTGACTACGA CTTCAACAGC TACAGACAGT
301 AAGTTACAAG CGACTGAAGT TAAGAGCGTT CCGGTAGCAC AAAAAGCTCC AACAGCAACA
361 CCGGTAGCAC AACCAGCTTC AACAACAAAT GCAGTAGCTG CACATCCTGA AAATGCAGGG
421 CTCCAACCTC ATGTTGCAGC TTATAAAGAA AAAGTAGCGT CAACTTATGG AGTTAATGAA
481 TTCAGTACAT ACCGTGCAGG TGATCCAGGT GATCATGGTA AAGGTTTAGC AGTCGACTTT
541 ATTGTAGGTA AAAACCAAGC ACTTGGAAT GAAGTTGCAC AGTACTCTAC ACAAATATG
601 GCAGCAAATA ACATTTTATA TGTTATCTGG CAACAAAAGT TTTACTCAAA TACAATAGT
661 ATTTATGGAC CTGCTAATAC TTGGAATGCA ATGCCAGATC GTGGTGGCGT TACTGCCAAC
721 CATTATGACC ATGTTACAGT ATCATTTAAC AAA

```

Figure 12 (SEQ ID NO: 12)

```

1 AANEQVSTAP VKSITSEVPA AKEEVKPTQT SVSQSTTVSP ASVAAETPAP VAKVAPVRTV
61 AAPRVASVKV VTPKVETGAS PEHVSAPAVP VTTTSTATDS KLQATEVKS VPAQKAPTAT
121 PVAQPASTTN AVAAHPENAG LQPHVAAYKE KVAITYGVNE FSTYRAGDPG DHGKGLAVDF
181 IVGKNQALGN EVAQYSTQNM AANNISYVIW QQKFYSNTNS IYGPANTWNA MPDRGGVTAN
241 HYDHVHVSN K

```

Figure 13 (SEQ ID NO: 13)

```

1 GGTATGACAC CAGAAGCAGC AACAAACGATT GTTTCGCCAA TGAAGACATA TTCTTCTGCG
61 CCAGCTTTGA AATCAAAAGA AGTATTAGCA CAAGAGCAAG CTGTTAGTCA AGCAGCAGCT
121 AATGAACAGG TATCAACAGC TCCTGTGAAG TCGATTACTT CAGAAGTTCC AGCAGCTAAA
181 GAGGAAGTTA AACCAACTCA GACGTCAGTC AGTCAGTCAA CAACAGTATC ACCAGCTTCT
241 GTTGCCGCTG AAACACCAGC TCCAGTAGCT AAAGTAGCAC CGGTAAGAAC TGTAGCAGCC
301 CCTAGAGTGG CAAGTGTTAA AGTAGTCACT CCTAAAGTAG AAAGTGGTGC ATCACCAGAG
361 CATGTATCAG CTCCAGCAGT TCCTGTGACT ACGACTTCAA CAGCTACAGA CAGTAAGTTA
421 CAAGCGACTG AAGTTAAGAG CGTTCGGGTA GCACAAAAAG CTCCAACAGC AACACCGGTA
481 GCACAACCAG CTTCACAAC AAATGCAGTA GCTGCACATC CTGAAAATGC A

```

Figure 14 (SEQ ID NO: 14)

```

1 GMTPEAATTI VSPMKTYSSA PALKSKEVLA QEQAVSQAAA NEQVSTAPVK SITSEVPAAK
61 EEVKPTQTSV SQSTTVSPAS VAAETPAPVA KVAPVRTVAA PRVASVKVVT PKVETGASPE
121 HVSAPAVPVT TTSTATDSKL QATEVKSVPV AQKAPTATPV AQPASTTNAV AAHPENA

```

Figure 15 (SEQ ID NO: 15)

```

1 GCAGGGCTCC AACCTCATGT TGCAGCTTAT AAAGAAAAAG TAGCGTCAAC TTATGGAGTT
61 AATGAATTC AATCAATACCG TGCAGGTGAT CCAGGTGATC ATGGTAAAGG TTTAGCAGTC
121 GACTTTATG TAGGTAAAAA CCAAGCACTT GGTAATGAAG TTGCACAGTA CTCTACACAA
181 AATATGGCAG CAAATAACAT TTCATATGTT ATCTGGCAAC AAAAGTTTTA CTCAAATACA
241 AATAGTATTT ATGGACCTGC TAATACTTGG AATGCAATGC CAGATCGTGG TGGCGTTACT
301 GCCAACCATT ATGACCATGT TCACGTATCA TTTAACAAA

```

Figure 16 (SEQ ID NO: 16)

```

1 AGLQPHVAAY KEKVASTYGV NEFSTYRAGD PGDHGKGLAV DFIVGKNQAL GNEVAQYSTQ
61 NMAANNISYV IWQQKFYSNT NSIYGPANTW NAMPDREGVT ANHYDHVHVS FNK

```

Figure 17 (SEQ ID NO: 17)

```

1 GGTAAAAACC AAGCACTTGG TAATGAAGTT GCACAGTACT CTACACAAAA TATGGCAGCA
61 AATAACATTT CATATGTTAT CTGGCAACAA AAGTTTTACT CAAATACAAA TAGTATTTAT
121 GGACCTGCTA ATACTTGGAA TGCAATGCCA GATCGTGGTG GCGTTACTGC CAACCATTAT
181 GACCATGTTC ACGTATCATT TAACAAA

```

Figure 18 (SEQ ID NO: 18)

```

1 GKNQALGNEV AQYSTQNMAA NNISYVIWQQ KFYSNTNSIY GPANTWNAMP DRGGVTANHY
61 DHVHVSFNK

```

Figure 19 (SEQ ID NO: 19)

```

1 GTTATCTGGC AACAAAAGTT TTAATCAAAT ACAAATAGTA TTTATGGACC TGCTAATACT
61 TGGAATGCAA TGCCAGATCG TGGTGGCGTT ACTGCCAACC ATTATGACCA TGTTCACGTA
121 TCATTTAACA AA

```

Figure 20 (SEQ ID NO: 20)

```

1 VIWQQKFYSN TNSIYGPANT WNAMPDRGGV TANHYDHVHV SFNK

```

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068813 A3

(51) International Patent Classification⁷: **C12N 15/31**,
15/62, C07K 14/315, A61K 39/09, C07K 16/12, G01N
33/53

(74) Agents: **MORROW, Joy, D.** et al.; Smart & Biggar, P.O.
Box 2999, Station D, 900-55 Metcalfe Street, Ottawa, On-
tario K1P 5Y6 (CA).

(21) International Application Number: PCT/CA03/00186

(22) International Filing Date: 11 February 2003 (11.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/354,947 11 February 2002 (11.02.2002) US

(71) Applicant (for all designated States except US): **SHIRE
BIOCHEM INC** [CA/CA]; 275 Armand-Frappier Boule-
vard, Laval, Quebec H7V 4A7 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RIOUX, Stéphane**
[CA/CA]; 869 Avenue Des Pinsons, Beauport, Québec
G1E 1J3 (CA). **MARTIN, Denis** [CA/CA]; 4728-G
Gaboury, St-Augustin-de-Desmaures, Québec G3A 1E9
(CA). **HAMEL, Josée** [CA/CA]; 2401 Maritain, Sillery,
Quebec G1T 1N6 (CA). **BRODEUR, Bernard, R.**
[CA/CA]; 2401 Maritain, Sillery, Québec G1T 1N6 (CA).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
16 October 2003

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: GROUP B STREPTOCOCCUS ANTIGEN

(57) Abstract: The present invention relates to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B streptococcus (GBS), also called Streptococcus Agalactiae which may be used to prevent, diagnose and/or treat streptococcal infection.



WO 03/068813 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 03/00186

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C12N15/62 C07K14/315 A61K39/09 C07K16/12
G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 32882 A (HANNIFFY SEAN BOSCO ;LE PAGE RICHARD WILLIAM FALLA (GB); WELLS JER) 10 May 2001 (2001-05-10) SEQ.ID.NO:148	1-30
X	----- DATABASE SWALL 'Online! EBI; 1 December 2001 (2001-12-01) "Truncated group B streptococcal surface immunogenic protein (SIP)" Database accession no. Q93GJ8 XP002247834	1-30
X	----- WO 99 42588 A (BIOCHEM VACCINS INC ;BRODEUR BERNARD R (CA); CHARLEBOIS ISABELLE () 26 August 1999 (1999-08-26) cited in the application figures 7C,9A ----- -/-	1-30

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

16 July 2003

Date of mailing of the international search report

28/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 03/00186

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BRODEUR B R ET AL: "Identification of group B streptococcal Sip protein, which elicits cross-protective immunity" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 68, no. 10, October 2000 (2000-10), pages 5610-5618, XP002219117 ISSN: 0019-9567 cited in the application figure 2</p> <p>-----</p>	1-30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 03/00186

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 22-26 and 29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 03/00186

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0132882	A	10-05-2001	CA 2382455 A1	10-05-2001
			CN 1377410 T	30-10-2002
			EP 1214417 A2	19-06-2002
			WO 0132882 A2	10-05-2001
<hr/>				
WO 9942588	A	26-08-1999	AU 2505999 A	06-09-1999
			CA 2321106 A1	26-08-1999
			WO 9942588 A2	26-08-1999
			CN 1297482 T	30-05-2001
			EP 1054971 A2	29-11-2000
			HU 0102304 A2	28-10-2001
			JP 2002507396 T	12-03-2002
			NO 20004161 A	19-10-2000
			TR 200002437 T2	21-11-2000
			US 2003031682 A1	13-02-2003
			ZA 9901325 A	20-08-1999
<hr/>				